13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
![](/mel/img/quote_button.gif) |
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
92,020 |
09.07.24 17:35:44 |
-0,060 |
-0,07% |
0,000 |
0,000 |
92,270 |
92,080 |
![](/mel/img/quote_button.gif) |
Regeneron Pharmaceuticals |
881535 |
NASDAQ |
1.054,755 |
09.07.24 21:32:08 |
+2,505 |
+0,24% |
1.053,980 |
1.055,560 |
1.055,830 |
1.052,250 |